FCDCX
Price
$41.16
Change
-$0.04 (-0.10%)
Updated
Jul 31 closing price
Net Assets
7.38B
VSCIX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

FCDCX vs VSCIX

FCDCX vs VSCIX Comparison Chart in %
View a ticker or compare two or three
VS
FCDCX vs. VSCIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FCDCX is a Buy and VSCIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 189B vs. FCDCX (7.38B). VSCIX pays higher dividends than FCDCX: VSCIX (1.23) vs FCDCX (0.00). FCDCX was incepted earlier than VSCIX: FCDCX (19 years) vs VSCIX (29 years). FCDCX (1.89) is less costly to investors than VSCIX (0.03). FCDCX is a more actively managed with annual turnover of: 46.00 vs. VSCIX (17.00). FCDCX has a lower initial minimum investment than VSCIX: FCDCX (0) vs VSCIX (5000000). FCDCX annual gain was more profitable for investors over the last year : 33.38 vs. VSCIX (22.58). FCDCX (36.68) and VSCIX (35.13) have equivalent 5 years return.
FCDCXVSCIXFCDCX / VSCIX
Total Expense Ratio1.890.036,300%
Annual Report Gross Expense Ratio1.890.036,300%
Fund Existence19 years29 years-
Gain YTD18.96014.591130%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets7.38B189B4%
Annual Yield % from dividends0.001.23-
Returns for 1 year33.3822.58148%
Returns for 3 years54.4743.44125%
Returns for 5 years36.6835.13104%
Returns for 10 years85.66156.0755%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPKX20.050.12
+0.60%
Goldman Sachs US Eq Div and Prem Instl
GSIQX23.62N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R
HSIIX29.59-0.08
-0.27%
Carillon Eagle Small Cap Growth I
CCWSX21.56-0.16
-0.74%
Baird Chautauqua International Gr Inv
RYCFX49.56-1.15
-2.27%
Rydex Biotechnology C